vs
Side-by-side financial comparison of Eightco Holdings Inc. (ORBS) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
Xilio Therapeutics, Inc. is the larger business by last-quarter revenue ($13.7M vs $10.2M, roughly 1.3× Eightco Holdings Inc.). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs -2281.6%, a 2357.3% gap on every dollar of revenue. Xilio Therapeutics, Inc. produced more free cash flow last quarter ($-2.1M vs $-11.0M).
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
ORBS vs XLO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.2M | $13.7M |
| Net Profit | $-232.5M | $10.4M |
| Gross Margin | -13.0% | — |
| Operating Margin | -475.0% | -86.5% |
| Net Margin | -2281.6% | 75.7% |
| Revenue YoY | -49.9% | — |
| Net Profit YoY | -9183.3% | 179.1% |
| EPS (diluted) | $-2.34 | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $10.2M | $13.7M | ||
| Q3 25 | $5.3M | $19.1M | ||
| Q2 25 | $7.6M | $8.1M | ||
| Q1 25 | $9.9M | $2.9M | ||
| Q4 24 | $20.3M | — | ||
| Q3 24 | $6.1M | — | ||
| Q2 24 | $5.3M | — | ||
| Q1 24 | $8.0M | — |
| Q4 25 | $-232.5M | $10.4M | ||
| Q3 25 | $-25.8M | $-16.3M | ||
| Q2 25 | $-1.2M | $-15.8M | ||
| Q1 25 | $-2.5M | $-13.3M | ||
| Q4 24 | $-2.5M | — | ||
| Q3 24 | $-3.2M | — | ||
| Q2 24 | $4.4M | — | ||
| Q1 24 | $1.9M | — |
| Q4 25 | -13.0% | — | ||
| Q3 25 | -3.7% | — | ||
| Q2 25 | 16.4% | — | ||
| Q1 25 | 8.2% | — | ||
| Q4 24 | 8.2% | — | ||
| Q3 24 | 26.5% | — | ||
| Q2 24 | 25.1% | — | ||
| Q1 24 | 17.5% | — |
| Q4 25 | -475.0% | -86.5% | ||
| Q3 25 | -116.9% | -10.1% | ||
| Q2 25 | -15.9% | -177.7% | ||
| Q1 25 | -14.3% | -472.7% | ||
| Q4 24 | -11.9% | — | ||
| Q3 24 | -29.1% | — | ||
| Q2 24 | -16.4% | — | ||
| Q1 24 | -39.6% | — |
| Q4 25 | -2281.6% | 75.7% | ||
| Q3 25 | -487.6% | -85.4% | ||
| Q2 25 | -15.4% | -196.0% | ||
| Q1 25 | -25.7% | -452.7% | ||
| Q4 24 | -12.3% | — | ||
| Q3 24 | -52.5% | — | ||
| Q2 24 | 84.2% | — | ||
| Q1 24 | 24.4% | — |
| Q4 25 | $-2.34 | $-3.74 | ||
| Q3 25 | $-0.58 | $-0.11 | ||
| Q2 25 | $-0.38 | $-0.16 | ||
| Q1 25 | $-0.84 | $-0.18 | ||
| Q4 24 | $-1.44 | — | ||
| Q3 24 | $-1.77 | — | ||
| Q2 24 | $2.15 | — | ||
| Q1 24 | $1.42 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $58.5M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $232.6M | $35.3M |
| Total Assets | $250.2M | $154.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $58.5M | $137.5M | ||
| Q3 25 | $23.7M | $103.8M | ||
| Q2 25 | $696.3K | $121.6M | ||
| Q1 25 | $434.4K | $89.1M | ||
| Q4 24 | $239.2K | — | ||
| Q3 24 | $2.4M | — | ||
| Q2 24 | $363.1K | — | ||
| Q1 24 | $808.8K | — |
| Q4 25 | $232.6M | $35.3M | ||
| Q3 25 | $339.2M | $-8.1M | ||
| Q2 25 | $8.9M | $7.1M | ||
| Q1 25 | $9.7M | $10.7M | ||
| Q4 24 | $11.9M | — | ||
| Q3 24 | $13.0M | — | ||
| Q2 24 | $13.8M | — | ||
| Q1 24 | $3.9M | — |
| Q4 25 | $250.2M | $154.7M | ||
| Q3 25 | $355.5M | $133.7M | ||
| Q2 25 | $48.7M | $133.8M | ||
| Q1 25 | $47.6M | $103.7M | ||
| Q4 24 | $50.8M | — | ||
| Q3 24 | $49.2M | — | ||
| Q2 24 | $48.4M | — | ||
| Q1 24 | $50.2M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-11.0M | $-2.0M |
| Free Cash FlowOCF − Capex | $-11.0M | $-2.1M |
| FCF MarginFCF / Revenue | -107.7% | -15.3% |
| Capex IntensityCapex / Revenue | 0.0% | 0.7% |
| Cash ConversionOCF / Net Profit | — | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-11.0M | $-2.0M | ||
| Q3 25 | $-1.6M | $-17.5M | ||
| Q2 25 | $-659.2K | $-14.5M | ||
| Q1 25 | $999.8K | $29.0M | ||
| Q4 24 | $-6.6M | — | ||
| Q3 24 | $77.7K | — | ||
| Q2 24 | $-440.3K | — | ||
| Q1 24 | $-723.3K | — |
| Q4 25 | $-11.0M | $-2.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | $-661.3K | $-14.9M | ||
| Q1 25 | $999.7K | $29.0M | ||
| Q4 24 | $-6.6M | — | ||
| Q3 24 | $73.0K | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -107.7% | -15.3% | ||
| Q3 25 | — | — | ||
| Q2 25 | -8.7% | -184.0% | ||
| Q1 25 | 10.1% | 988.3% | ||
| Q4 24 | -32.7% | — | ||
| Q3 24 | 1.2% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 0.0% | 0.7% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.0% | 5.0% | ||
| Q1 25 | 0.0% | 0.8% | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -0.19× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -0.10× | — | ||
| Q1 24 | -0.37× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
